Reports Q2 revenue $13.129M, consensus $9.39M. “We continue to add to our diversified portfolio of both early- and late-stage assets through disciplined capital deployment and creative financial structures,” stated Owen Hughes, Chief Executive Officer of XOMA (XOMA) Royalty. “Recently approved drugs are addressing key unmet patient needs, which is driving increased royalty receipts, and we await data from several key Phase 3 assets over the coming quarters.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA:
- Xoma closes tender offer for Turnstone Biologics
- Xoma’s Strategic Acquisitions and Royalty Expansion Drive Buy Rating
- Xoma to acquire Lava Therapeutics for $1.16-$1.24 per share in cash plus CVR
- HilleVax to be acquired by XOMA Royalty for $1.95 in cash per share plus CVR
- XenoTherapeutics to acquire Essa Pharma